Research Study

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT02255656
Status 
Closed to Recruitment
Study Start/End 
Mar 1, 2015 to Mar 1, 2020
Locations 
UBC Hospital
Name/Title 
Laura Harvey, Research Coordinator
Phone 
604-827-1334
Email Address 
laura.harvey@ubc.ca
Purpose of Study 

Primary Objective:

  • To evaluate long-term safety of alemtuzumab.

Secondary Objectives:

  • To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of patients who received other Disease Modifying Treatment's (DMT) following alemtuzumab treatment.
  • To evaluate patient-reported Quality of Life (QoL) outcomes and health resource utilization of patients who received alemtuzumab.
  • To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.